SWOG S2000: doublet IO vs triplet therapy in melanoma brain metastases скачать в хорошем качестве

SWOG S2000: doublet IO vs triplet therapy in melanoma brain metastases

Zeynep Eroglu, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the Phase II SWOG S2000 trial (NCT04511013), which compared a triplet regimen of encorafenib, binimetinib, and nivolumab to the combination of ipilimumab and nivolumab in patients with symptomatic BRAFV600-mutant melanoma brain metastases. The primary endpoint of intra- and extracranial progression-free survival was achieved in the triplet therapy arm. Response rates were higher with the triplet regimen, and the safety profile was consistent with previous data. These results highlight the potential of combining targeted therapy with immunotherapy for this difficult-to-treat patient group. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.